DOCSLIB.ORG

Hypoxanthine, Xanthine, and Uric Acid Concentrations in the Cerebrospinal Fluid, Plasma, and Urine of Hypoxemic Pigs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hypoxanthine, Xanthine, and Uric Acid Concentrations in the Cerebrospinal Fluid, Plasma, and Urine of Hypoxemic Pigs 003 1-3998{90/2805-0477$02 .00{0 PEDIATRIC RESEARCH Vol. 28, No.5, 1990 Copyright © 1990 International Pediatric Research Foundation, Inc. Printed in U.S. A. Hypoxanthine, Xanthine, and Uric Acid Concentrations in the Cerebrospinal Fluid, Plasma, and Urine of Hypoxemic Pigs JAN PETER POULSEN, STEPHAN IE 0YASJETER, JON SANDERUD, TORLEIV OLE ROGNUM, AND OLA DIDRI K SAUGSTAD Institutefor S urgical Research (J.P.P.. 1.S;. Institute fo r Pediatric Research [S.llJ.. O.D.S;. Institute ofForensic M edicine [T.O.R.;. and Department 0/Pediatrics [O.D.S},University a/Oslo. The National Hospital. N-0027 Oslo 1, Norway ABSTRACf. Th e concentrations of hypoxanthine, xan­ uate hypoxia , but to correlate a biochemically measured value thin e, and uric acid in plasma and cerebrospinal fluid with the outco me of hypoxia is difficult . Measurements of the (CSF), as well as the urinary output of hypoxanthine and purine metabolite hypoxanthine can be used as an indicator of xanthine, were measured in four groups of pigs (three hypoxia (I). Du ring tissue hypoxia, elevated hypoxanthine levels group s with differ ent degrees of hypoxemia and one control have been found in plasm a (2- 5), CSF (6, 7), and urine (8). group). During hypoxemia with arterial O, tension between However, no clear definition of clinical hypoxia is available, and 2.1 and 3.0 kPa [group 1, fractional inspired oxygen (FiOz) ma ny autho rs do not distinguish between the terms hypoxemia =0.081, hypoxanthine increased in CS F from a mean basal and hypoxia, which adds to the confusion. Our meaning of value of 18.1 to 39.3 umol /L at death ( p < 0.02 ), in plasma hypoxia has previously been described (I). In our study the pigs from 25.4 to 103.6 J.Lmol/L (p < 0.05 ), and in urine from were subjected to hypoxemia. We define hypoxe mia as deficient 21.3 to 87.1 nmol/kg/min (p < 0.02). Xanthine changed in oxygenation of the blood. Hypoxem ia may, however, not nec­ a similar way: in CSF from 4.0 to 10.6 umol /L (p < 0.02), essarily lead to tissue hypoxia. in plasma from 0.7 to 48.1 J.Lmol/L (p < 0.02), and in urine To further assess the usefulness of hypoxanthine as a biochem­ from 4.0 to 12.6 nmol/kg/min (p < 0.05). Uric acid in­ ical marker of hypoxia, we report how three degrees of hypox­ crea sed in CSF from 2.7 to 11.6 J.Lmol/L (p < 0.05), and emi a in young pigs influence the level ofhypoxanthine, xanthine, in plasma from 15.4 to 125.0 J.Lmol/L ( p < 0.02). During and uric acid in the CSF and plasma , as well as the pigs' urinary hypoxemia with arterial O 2 tension between 3.0 and 4.0 excretion of hypoxanthine and xanthine. kPa (group 2, Fi0 2 = 0.11), hypoxanthine increased in the CSF from 14.7 to 42.9 /-Lmol/L ( p < 0.02). Plasma hypo­ xanthine increased from 20.3 to a maximum of 44.1 J.Lmol/ MATER IALS AND METHODS L (p < 0.02), but decreased to initial values by the time of death. The urinary excretion of hypoxanthine increased Approval. The local hospital's ethical committee for animal from 13 to 54 nmol/kg /min (p < 0.02). Xanthine increased studies approved these experim ents. in the CS F from 3.9 to 13.3 J.L mol/L (p < 0.02), in plasma Animal model. The animal model was similar to that previ­ from 0.6 to 36.6 J.Lmol/L (p < 0.02 ), and in urine from 6 to ously described (9). Twent y-two young pigs of either sex (the 25 nmol/kg/min ( p < 0.02). Uric acid increa sed in CSF males had been castrated shortly after birth ) weighing 17-22 kg from 3.1 to 16.3 J.Lmol/L (p < 0.02), and in plasma from (mea n 18.1 kg) were used. They were anesthetized with an 15.3 to 208 J.Lmol/L (p < 0.02). During milder hypoxemia intraperitoneal injection of sodium pentobarbital (30 mg/kg). with arterial O. tension between 4.3 and 5.6 kPa (group 3, An i.v. line was established through an ear vein, and a contin uous Fi02 =0.14), or in the control group (group 4, Fi02 = infusion of Ringer acetate (10 mL/kg/h) was given during the 0.21), neither of the metabolites changed significantly. experiment. A further 100 mg of sodium pentobar bital was given (Pediatr Res 28: 477-481, 1990) i.v, if necessary every 30 min. A cuffed tube was placed in the trachea via a tracheostom y. Artificial ventilation was given by a Abbreviations ventilator (Servo-ventilator 900B, Elema-Schenander, Stoc k­ holm, Sweden). Ventilation rate and tidal volume were adjusted CSF, cerebrospinal fluid until Paco, ranged between 4 and 5.3 kPa (30-40 mm Hg). No FiO z, fractional inspired oxygen further adjustme nts of the ventilato r .were done du ring the hy­ Pao-, arterial O 2 tension poxemic period. Paco-, arterial CO 2 tension A midline suprapubic laparotomy was performed and a uri­ nary catheter was placed in the bladder for measuring diuresis and urinary hypoxanthine and xanthine. Hypoxia is a common insult during the perinatal and neonatal Polyethylene catheters were inserted into a femoral artery and period. Several biochemical measurements can be done to eval- a femoral vein. The arterial catheter was used for taking blood samples and for measuring blood pressure continuously with a Received Janu ary 15. 1990: accepted June 5, 1990. strai n gauge tra nsducer, Go uld recorde r 2600S (Gould Inc. Re­ Correspondence and reprint requests: Dr. Jan Peter Poulsen, Institute for Sur­ cording Systems, Cleveland, OH). Th e venous catheter was used gical Research, University of Oslo, The Nationa l Hospital, N-0027 Oslo 1, Norway. for giving Ringer acetate plus additional sodium pentobarbital. Supported by the Norwegian Wom en's Public Health Association, the Norwe­ Th e pigs were divided into three hypoxemic and one contro l gian Research Coun cil for Science and the Humanities, The Lrerdal Foundation for Acute Medicine. and Odd Fellow Medical Research Foundation. J.P.P. is a group. Seven animals were made hypoxemic by art ificial venti­ Research Fellow with The Norwegian Cancer Society. lation with 8% oxygen in nitrogen (FiOz = 0.08) (group 1). Seven 477 478 POULSEN ET AL. animals were ventilated with II % oxygen (Fi0 2 = 0.11) (group were checked by coelution with known pure standards. This was 2). Five animals were ventilated with 14% oxygen (Fi02 = 0.14) especi ally necess ary at low xanthine con centrations. (group 3), and three anima ls were ventilated with room air (Fi02 Quantificati on of peaks was done by peak height ratios. All = 0.2 1), servi ng as norm oxemic contro ls (group 4). The oxygen pure stan dards used for the HPLC were obtain ed from Sigm a conce ntratio ns were measured continuo usly in all pigs during Chemical Co., St. Lou is, MO. th e experime nts with a Dameca OM 83 1 oxygen m onitor (Da­ Uric acid was measured on an RA-I OOO(Tec hnicon In stru­ meca Inc., Copen hagen, Denmark). ments, Tarrytown , N Y), auto ma tic blood analyzer. During hyp oxemia with Fi02 = 0.08, the Pao, remained Statistics. Results are given as mean ± SO. Wilcoxon's two­ between 2.1 and 3.0 kPa (15. 8-22.5 m m Hg). This degree of tailed rank test was applied for testing th e significance of differ­ hypoxemia lasted until the animals died after a mean of 170 min ences between comparable groups. A p value <0.05 was consid­ (range 120-240 min). During hypoxemia with Fi02 = 0.11, the ered statistically significant. Pao, rem ain ed between 3.0 an d 4.0 kPa (22.5-30 mm Hg), and these pigs died after a mean of 283 min (ra nge 165-445 min ). RESULTS During the mildest hypoxemia (Fi0 2 = 0. 14), the Pa02 remained between 4.3 and 5.6 kPa (32.5-42 mm Hg). All anima ls tolerated Blood gases and mean arterial pressure. Tab le I shows th e th is degree of hypoxem ia for 480 m in, after which th ey were arterial Pao-, O2 sat uratio n, and mean arterial blood pressure in killed with an i.v. overdose of sodium pentobarbital. The pigs in the four groups of pigs. There were no differen ces between the the control group were observed from 185 to 480 m in and then groups before th e start of hypoxemia. In the animals with the killed. During artificial ventilatio n, I mL of pancuron ium bro­ two most severe degrees of hypoxemia, the re was an initial m ide (Pavu lon 2 mg/rnl., Organ on Tekn ika, Boxtel, Nether­ increase in blood pressure at the start of the hypoxemia, lasting lands) was given i.v. every 30 min to prevent muscular contrac­ for abou t I h. The blood pressure in both th ese gro ups th en tions, which may lead to artificially high hypox anthine levels gradually declined toward zero in th e term inal phase, as previ­ ( 10). ously described (13). No significan t cha nges in the mean Paco, Blood samples. Arteria l blood samples were taken after a were found in any gro up.
Load more

Recommended publications
  • SCH 58261: a Potent and Selective Non-Xanthine A2A Adenosine Receptor Antagonist
    22 DIRECTED DRUG DISCOVERY™ LIGAND-SETS™ for Assay Validation and High Throughput Screening Easy-to-use collections of pharmacologically-similar, small organic ligands Sigma-RBI LIGAND-SETS™ are a convenient and affordable way to screen a specific target with a collection of well- characterized, pharmacologically-active compounds. Each LIGAND-SET™ contains 40-80 high purity (>96%), small organic ligands arranged by pharmacological class in a 96-well format, one compound (2 mg) per well (1 ml capacity). N Standardize/validate new screening assays with well-characterized ligands N Guide secondary screening of larger, diverse libraries using pharmaceutically-relevant structures N Screen new drug targets for leads with pharmacologically-active compounds Nine different LIGAND-SETS™ are now available: N Adrenergics (Prod. No. L 0383) N Enzyme Inhibitors (Prod. No. L 6787) N Purines/Pyrimidines (Prod. No. L 2538) N Cholinergics (Prod. No. L 2663) N GABAergics (Prod. No. L 7884) N Glutamatergics (Prod. No. L 6537) N Dopaminergics (Prod. No. L 6412) N Ion Channel Modulators (Prod. No. L 6912) N Serotonergics (Prod. No. L 6662) For further information, please visit our Drug Discovery website at sigma-aldrich.com/drugdiscovery Technical information for each compound is provided in standard SD file format for use with ISIS/Base or other compatible software (software not provided). SCH 58261: A potent and selective non-xanthine A2A adenosine receptor antagonist Vol. 19 No. 4 Vol. Adenosine (Prod. No. A 9251) acts as a modulator of [3]. These results suggest a neuroprotective effect of this neuronal activity through its interaction with four receptor compound. In another study, the role of A1 and A2A subtypes referred to as A1, A2A, A2B and A3.
    [Show full text]
  • 35 Disorders of Purine and Pyrimidine Metabolism
    35 Disorders of Purine and Pyrimidine Metabolism Georges van den Berghe, M.- Françoise Vincent, Sandrine Marie 35.1 Inborn Errors of Purine Metabolism – 435 35.1.1 Phosphoribosyl Pyrophosphate Synthetase Superactivity – 435 35.1.2 Adenylosuccinase Deficiency – 436 35.1.3 AICA-Ribosiduria – 437 35.1.4 Muscle AMP Deaminase Deficiency – 437 35.1.5 Adenosine Deaminase Deficiency – 438 35.1.6 Adenosine Deaminase Superactivity – 439 35.1.7 Purine Nucleoside Phosphorylase Deficiency – 440 35.1.8 Xanthine Oxidase Deficiency – 440 35.1.9 Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency – 441 35.1.10 Adenine Phosphoribosyltransferase Deficiency – 442 35.1.11 Deoxyguanosine Kinase Deficiency – 442 35.2 Inborn Errors of Pyrimidine Metabolism – 445 35.2.1 UMP Synthase Deficiency (Hereditary Orotic Aciduria) – 445 35.2.2 Dihydropyrimidine Dehydrogenase Deficiency – 445 35.2.3 Dihydropyrimidinase Deficiency – 446 35.2.4 Ureidopropionase Deficiency – 446 35.2.5 Pyrimidine 5’-Nucleotidase Deficiency – 446 35.2.6 Cytosolic 5’-Nucleotidase Superactivity – 447 35.2.7 Thymidine Phosphorylase Deficiency – 447 35.2.8 Thymidine Kinase Deficiency – 447 References – 447 434 Chapter 35 · Disorders of Purine and Pyrimidine Metabolism Purine Metabolism Purine nucleotides are essential cellular constituents 4 The catabolic pathway starts from GMP, IMP and which intervene in energy transfer, metabolic regula- AMP, and produces uric acid, a poorly soluble tion, and synthesis of DNA and RNA. Purine metabo- compound, which tends to crystallize once its lism can be divided into three pathways: plasma concentration surpasses 6.5–7 mg/dl (0.38– 4 The biosynthetic pathway, often termed de novo, 0.47 mmol/l). starts with the formation of phosphoribosyl pyro- 4 The salvage pathway utilizes the purine bases, gua- phosphate (PRPP) and leads to the synthesis of nine, hypoxanthine and adenine, which are pro- inosine monophosphate (IMP).
    [Show full text]
  • Effect of Theophylline and Enprofylline on Bronchial Hyperresponsiveness
    Thorax: first published as 10.1136/thx.44.12.1022 on 1 December 1989. Downloaded from Thorax 1989;44:1022-1026 Effect of theophylline and enprofylline on bronchial hyperresponsiveness G H KOETER, J KRAAN, M BOORSMA, J H G JONKMAN, TH W VAN DER MARK From the Department ofPulmonology and Lung Function, University Hospital, Groningen; Pharma Bio Research, Assen; and Astra Pharmaceutica, Rijswijk, The Netherlands ABSTRACT The effect of increasing intravenous doses of theophylline and enprofylline, a new xanthine derivative, on bronchial responsiveness to methacholine was studied in eight asthmatic patients. Methacholine provocations were carried out on three days before and after increasing doses of theophylline, enprofylline, and placebo, a double blind study design being used. Methacholine responsiveness was determined as the provocative concentration of methacholine causing a fall of 20% in FEV, (PC20). The patients were characterised pharmacokinetically before the main study to provide an individual dosage scheme for each patient that would provide rapid steady state plasma concentration plateaus of 5, 10, and 15 mg/l for theophylline and 1 25, 2 5, and 3-75 mg/l for enprofylline. Dose increments in the main study were given at 90 minute intervals. FEV, showed a small progressive decrease after placebo; it remained high in relation to placebo after both drugs and this effect was dose related. Methacholine PC20 values decreased after placebo; mean values were (maximum difference 2-0 and 1 7 higher after theophylline and enprofylline than after placebo copyright. doubling doses of methacholine); the effect of both drugs was dose related. Thus enprofylline and theophylline when given intravenously cause a small dose related increase in FEV1 and methacholine PC20 when compared with placebo.
    [Show full text]
  • Pro-Aging Effects of Xanthine Oxidoreductase Products
    antioxidants Review Pro-Aging Effects of Xanthine Oxidoreductase Products , , Maria Giulia Battelli y , Massimo Bortolotti y , Andrea Bolognesi * z and Letizia Polito * z Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, University of Bologna, Via San Giacomo 14, 40126 Bologna, Italy; [email protected] (M.G.B.); [email protected] (M.B.) * Correspondence: [email protected] (A.B.); [email protected] (L.P.); Tel.: +39-051-20-9-4707 (A.B.); +39-051-20-9-4729 (L.P.) These authors contributed equally. y Co-last authors. z Received: 22 July 2020; Accepted: 4 September 2020; Published: 8 September 2020 Abstract: The senescence process is the result of a series of factors that start from the genetic constitution interacting with epigenetic modifications induced by endogenous and environmental causes and that lead to a progressive deterioration at the cellular and functional levels. One of the main causes of aging is oxidative stress deriving from the imbalance between the production of reactive oxygen (ROS) and nitrogen (RNS) species and their scavenging through antioxidants. Xanthine oxidoreductase (XOR) activities produce uric acid, as well as reactive oxygen and nitrogen species, which all may be relevant to such equilibrium. This review analyzes XOR activity through in vitro experiments, animal studies and clinical reports, which highlight the pro-aging effects of XOR products. However, XOR activity contributes to a regular level of ROS and RNS, which appears essential for the proper functioning of many physiological pathways. This discourages the use of therapies with XOR inhibitors, unless symptomatic hyperuricemia is present.
    [Show full text]
  • COPD Agents Review – October 2020 Page 2 | Proprietary Information
    COPD Agents Therapeutic Class Review (TCR) October 1, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. October 2020
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
    [Show full text]
  • Thermostable and Long-Circulating Albumin-Conjugated Arthrobacter Globiformis Urate Oxidase
    pharmaceutics Article Thermostable and Long-Circulating Albumin-Conjugated Arthrobacter globiformis Urate Oxidase Byungseop Yang and Inchan Kwon * School of Materials Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju 61005, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-62-715-2312 Abstract: Urate oxidase derived from Aspergillus flavus has been investigated as a treatment for tumor lysis syndrome, hyperuricemia, and gout. However, its long-term use is limited owing to potential immunogenicity, low thermostability, and short circulation time in vivo. Recently, urate oxidase isolated from Arthrobacter globiformis (AgUox) has been reported to be thermostable and less immunogenic than the Aspergillus-derived urate oxidase. Conjugation of human serum albumin (HSA) to therapeutic proteins has become a promising strategy to prolong circulation time in vivo. To develop a thermostable and long-circulating urate oxidase, we investigated the site-specific conjugation of HSA to AgUox based on site-specific incorporation of a clickable non-natural amino acid (frTet) and an inverse electron demand Diels–Alder reaction. We selected 14 sites for frTet incorporation using the ROSETTA design, a computational stability prediction program, among which AgUox containing frTet at position 196 (Ag12) exhibited enzymatic activity and thermostability comparable to those of wild-type AgUox. Furthermore, Ag12 exhibited a high HSA conjugation yield without compromising the enzymatic activity, generating well-defined HSA-conjugated AgUox (Ag12-HSA). In mice, the serum half-life of Ag12-HSA was approximately 29 h, which was roughly Citation: Yang, B.; Kwon, I. 17-fold longer than that of wild-type AgUox. Altogether, this novel formulated AgUox may hold Thermostable and Long-Circulating enhanced therapeutic efficacy for several diseases.
    [Show full text]
  • Alternative Pathways of Glucose Metabolism II. Nucleotides from The
    Alternative Pathways of Glucose Metabolism II . Nucleotides from the Acid-soluble Fraction of Normal and Tumor Tissues and Studies on Nucleic Acid Synthesis in Tumors*t HANNS SCHMITZ4 VAN R. POTTER, ROBERT B. HTJRLBERT,@ AND DWAIN M. WHITE (McArdie Memovial Laboratory, the Medical School, University of Wisconain, Madison, WI..) The first paper (18) in this series on the alterna MATERIALS AND METHODS tive pathways of glucose metabolism established The present study has involved the measure the fact that radioactivity from glucose-i-C'4 was ment of the specific activities of the free 5' mono-, readily incorporated into the pentose moiety of the di-, and triphosphates of adenosine, guanosine, ribonucleic and desoxyribonucleic acids of Flexner cytidine, and uridine from the acid-soluble extract Jobling tumors in rats, and described the over-all of tumor tissue in relation to the specific activities distribution of radioactivity in the acid-soluble of the corresponding nucleotides that were oh and acid-insoluble fractions of tumor and liver tis tamed by chemical or enzymatic hydrolysis of the sue at various time periods. The acid-soluble frac nucleic acids from the same tissue samples, at tion of tissue contains an appreciable amount of specified time intervals after the injection of glu free nucleotides which are possible intermediary cose-1-C'4. The experimental plan corresponds compounds in the synthesis of the nucleic acids exactly to that described in the preceding paper; (6, 7, 8, 9, 13, 16). It was noted (18) that as the C'4 many of
    [Show full text]
  • Low Uric Acid Diet Diet FAQ's What Is Uricvs Acid? Uric Acid Is a Byproduct of Purines (PYUR-Eenz)
    o ?? ou need t Y our reduce y Uric Acid! Understanding the Low Uric Acid Diet Diet FAQ's What is Uricvs Acid? Uric acid is a byproduct of purines (PYUR-eenz). Purines are naturally occurring substances and are found in many food items. As purines are broken down in the body, they are eliminated as uric acid. What does Uric Acid have to do with CKD? Normally, uric acid passes through the kidneys and is excreted in urine. However, when the kidneys cannot process all of the uric acid, hyperuricemia, or elevated uric acid in the blood, may develop. Recent research has determined that approximately 10% of Americans with Chronic Kidney Disease (CKD) also have gout, and if left untreated, can further worsen kidney function. Why do I need a diet that reduces Uric Acid? When your kidneys are not functioning properly, they do not filter out uric acid properly, thus potentially leading to a number of health issues. Elevated hyperuricemia (elevated uric acid levels) may cause: • Worsening of kidney function • Flare up of gout • Damage to affected joints Diet Do's and Don'ts Do Don't DO Don't Do Don't Exercise: even 1 minute of moderate to brisk Don’t take baker’s yeast or brewer’s yeast as a walking is helpful supplement Drink 8-12 cups o f fluid daily, this may help reduce Don't drink ( or try to limit) alcohol. Alcohol increases kidney stone formation and decrease uric acid purine production, thus further worsening crystals hyperuricemia Foods to limit Limit meat to 3 ounces per meal Limit high fat foods, such as salad dressings, ice cream, fried foods, & gravies.
    [Show full text]
  • Study of Purine Metabolism in a Xanthinuric Female
    Study of Purine Metabolism in a Xanthinuric Female MICHAEL J. BRADFORD, IRWIN H. KRAKOFF, ROBERT LEEPER, and M. EARL BALis From the Sloan-Kettering Institute, Sloan-Kettering Division of Cornell University Graduate School of Medical Sciences, and the Department of Medicine of Memorial and James Ewing Hospitals, New York 10021 A B S TR A C T A case of xanthinuria is briefly de- Case report in brief. The patient is a 62 yr old scribed, and the results of in vivo studies with Puerto Rican grandmother, whose illness is de- 4C-labeled oxypurines are discussed. The data scribed in detail elsewhere.' Except for mild pso- demonstrate that the rate of the turnover of uric riasis present for 30 yr, she has been in good acid is normal, despite an extremely small uric health. On 26 June 1966, the patient was admitted acid pool. Xanthine and hypoxanthine pools were to the Second (Cornell) Medical Service, Bellevue measured and their metabolism evaluated. The Hospital, with a 3 day history of pain in the right bulk of the daily pool of 276 mg of xanthine, but foot and fever. The admission physical examina- only 6% of the 960 mg of hypoxanthine, is ex- tion confirmed the presence of monoarticular ar- creted. Thus, xanthine appears to be a metabolic thritis and mild psoriasis. The patient's course in end product, whereas hypoxanthine is an active the hospital was characterized by recurrent fevers intermediate. Biochemical implications of this find- to 104°F and migratory polyarthritis, affecting ing are discussed. both ankles, knees, elbows, wrists, and hands over a 6 wk period.
    [Show full text]
  • Nouriast Tablets 20 Mg [Non-Proprietary Name] Istradefylline (JAN*) [Applicant] Kyowa Hakko Kirin Co., Ltd
    Report on the Deliberation Results March 15, 2013 Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare [Brand name] Nouriast Tablets 20 mg [Non-proprietary name] Istradefylline (JAN*) [Applicant] Kyowa Hakko Kirin Co., Ltd. [Date of application] March 30, 2012 [Results of deliberation] In the meeting held on March 8, 2013, the First Committee on New Drugs concluded that the product may be approved and that this result should be reported to the Pharmaceutical Affairs Department of the Pharmaceutical Affairs and Food Sanitation Council. The product is not classified as a biological product or a specified biological product, the re-examination period is 8 years, and neither the drug substance nor the drug product is classified as a poisonous drug or a powerful drug. *Japanese Accepted Name (modified INN) This English version of the Japanese review report is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. The PMDA will not be responsible for any consequence resulting from the use of this English version. Review Report February 22, 2013 Pharmaceuticals and Medical Devices Agency The results of a regulatory review conducted by the Pharmaceuticals and Medical Devices Agency on the following pharmaceutical product submitted for registration are as follows. [Brand name] Nouriast Tablets 20 mg [Non-proprietary name] Istradefylline [Name of applicant]
    [Show full text]
  • A 1 Adenosine Receptor Agonists and Antiagonists
    Europaisches Patentamt (19) European Patent Office Office europeenpeen des brevets EP 0 725 782 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) intci.6: C07D 473/08, C07H 19/167, of the grant of the patent: C07D 519/00, A61K 31/52 15.12.1999 Bulletin 1999/50 // (C07D51 9/00, 493:00, 473:00) (21) Application number: 95901070.3 (86) International application number: PCT/US94/12388 (22) Date of filing: 28.10.1994 (87) International publication number: WO 95/11904 (04.05.1995 Gazette 1995/19) (54) A 1 ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS A1 ADENOSIN REZEPTOR AGONISTEN UND ANTAGONISTEN AGONISTES ET ANTAGONISTES DE RECEPTEURS DE L'ADENOSINE A 1 (84) Designated Contracting States: • SCAMMELLS, Peter, J. AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL Highton, VIC 3216 (AU) PT SE • MILNER, Peter, Gerard Los Altos, CA 94022 (US) (30) Priority: 28.10.1993 US 144459 • PFISTER, Jurg, Roland Los Altos, CA 94024 (US) (43) Date of publication of application: • SCHREINER, George, Frederic 14.08.1996 Bulletin 1996/33 Los Altos, CA 94022 (US) (73) Proprietor: UNIVERSITY OF FLORIDA (74) Representative: Perry, Robert Edward RESEARCH FOUNDATION, INC. GILL JENNINGS & EVERY Gainesville, FL 32611 (US) Broadgate House 7 Eldon Street (72) Inventors: London EC2M 7LH (GB) • BELARDINELLI, Luiz Gainesville, FL 32605 (US) (56) References cited: • OLSSON, Ray EP-A- 0 374 808 EP-A- 0 415 456 Tampa, FL 33609-3504 (US) WO-A-92/00297 WO-A-94/16702 • BAKER, Stephen DE-A- 4 205 306 US-A- 5 288 721 Gainesville, FL 32607 (US) DO CM 00 Is- lO CM Is- Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice the Patent Office of the Notice of shall be filed in o to European opposition to European patent granted.
    [Show full text]